SCHEMBL2264771

SCHEMBL2264771

Fc1cc(Cl)cc2c1CCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.37
SOS1 Q07889 1/20 0.36
HTR2C P28335 3/20 0.36
HTR2A P28223 2/20 0.36
HTR2B P41595 2/20 0.36
PARP1 P09874 1/20 0.35
DRD4 P21917 4/20 0.34
DRD2 P14416 3/20 0.34
GRIN1 Q05586 2/20 0.31
GRIN2A Q12879 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
PNMT P11086 1/20 0.31
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290576 0.78 BCL2L1 (0.42) PARP1DRD4DRD2GRIN1GRIN2A
SCHEMBL30047627 0.78 MAOA (0.37) SOS1DRD4DRD2GRIN1GRIN2A
SCHEMBL28908910 0.78 MAOA (0.37) SOS1DRD4DRD2GRIN1GRIN2A
SCHEMBL4644733 0.77 MAOA (0.33) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL15129334 0.77 ADRA2A (0.40) ARHTR2CHTR2AHTR2BPARP1
SCHEMBL31741019 0.77 ADRA2A (0.40) ARHTR2CHTR2AHTR2BPARP1
SCHEMBL156631 0.76 MEN1 (0.37) HTR2CHTR2AHTR2BPARP1DRD4
SCHEMBL19679237 0.74 BCL2L1 (0.47) HTR2CGRIN1GRIN2AKDM4ELMNA
SCHEMBL30686151 0.74 MAPT (0.34) PARP1GRIN1GRIN2ALMNAACHE
SCHEMBL12490226 0.74 MAPT (0.34) PARP1GRIN1GRIN2ALMNAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201590-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF SANOFI-AVENTIS (FR) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201590-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF CFTR, AADAT, PKD1 AR 3149/4885SOS1 4224/4885HTR2C 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.